<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470468</url>
  </required_header>
  <id_info>
    <org_study_id>SLU01</org_study_id>
    <secondary_id>2014-003084-37</secondary_id>
    <nct_id>NCT02470468</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer</brief_title>
  <official_title>A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune
      enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression
      free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune
      enhancers vs. Standard of Care chemotherapy alone in patients with stage IV NSCLC, as
      measured by progression free survival (PFS).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).</measure>
    <time_frame>17 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of safety in patients treated with DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone. (AEs, SAEs, laboratory abnormalities, vital signs)</measure>
    <time_frame>17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further comparison of efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone, as measured by objective response rate and duration of response (per RECIST 1.1).</measure>
    <time_frame>17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further comparison of efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone, as measured by overall survival.</measure>
    <time_frame>17 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC add on to SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCVAC and immune enhancers add on to SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care chemotherapy (Carboplatin, Paclitaxel)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC add on to SOC</intervention_name>
    <description>DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death</description>
    <arm_group_label>DCVAC add on to SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC and immune enhancers add on to SOC</intervention_name>
    <description>DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death</description>
    <arm_group_label>DCVAC and immune enhancers add on to SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care Chemotherapy</intervention_name>
    <description>SOC (Carboplatin, Paclitaxel): until progression or intolerance or death</description>
    <arm_group_label>Standard of Care Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of either
             adenomatous or squamous cell carcinoma differentiation; mixed tumors will be
             categorized by the predominant cell type.

          2. Advanced NSCLC (stage IV unresectable disease)

          3. Patients must have measurable or non-measurable disease

          4. Patients (male and female) ≥ 18 years

          5. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1 6. Patients must have
             recovered from toxicity of any prior therapy (e.g. surgery, radiotherapy, or therapy
             for other diseases than NSCLC). Recovery is defined as less than or equal to grade 2
             toxicity according (except alopecia) to NCI CTCAE 7. Laboratory criteria 7.1 Platelet
             count of at least 100,000/mm3 (100 x 109/L) 7.2 White blood cells (WBC) greater than
             4,000/mm3 (4.0 x109/L) 7.3 Hemoglobin (Hb) at least 9g/dL (90 g/L) 7.4 Total bilirubin
             levels ≤1.5mg/dL (benign hereditary hyper-bilirubinemias, e.g., Gilbert´s syndrome are
             permitted) 7.5 Serum alanine aminotransferase and aspartate aminotransferase ≤ 5 times
             the upper limit of normal (ULN) 7.6 Serum creatinine ≤ 1.5 times the upper limit of
             normal (ULN)

        8. Women of childbearing potential and sexually active males must agree to use an accepted
        and effective method of contraception (hormonal or barrier methods, abstinence) prior to
        study entry and for the duration of the treatment plus 3 months.

        9. Signed informed consent including patient's ability to comprehend its contents. (Consent
        to genetic testing is not a condition for participation in the clinical trial)

        Exclusion Criteria:

          1. Prior chemotherapy for stage IV NSCLC

          2. Immunotherapy, monoclonal antibodies received within 4 weeks prior to randomization

          3. Patients comorbidities 3.1 Patients who are not indicated for chemotherapy treatment
             with first line Standard of Care chemotherapy (carboplatin/paclitaxel) 3.2 Active
             other malignancy than NSCLC 3.3 Known central nervous system (CNS) metastases 3.4 Any
             disease requiring chronic steroid or immunosuppressive therapy 3.5 HIV positive 3.6
             Active hepatitis B (HBV) and/or C (HCV), active syphilis 3.7 Ongoing/active
             significant infection or other severe medical condition 3.8 Pre-existing thyroid
             disease unless it can be controlled with conventional treatment 3.9 Clinically
             significant cardiovascular disease including: 3.9.1 Uncontrolled congestive heart
             failure 3.9.2 Unstable angina pectoris 3.9.3 Uncontrolled severe cardiac arrhythmia
             3.9.4 Myocardial infarction within 6 months prior randomization 3.10 Psychiatric
             illness/social situations that would limit compliance with study requirements

          4. Pregnant or breast feeding women

          5. Participation in a clinical trial using experimental therapy within the last 4 weeks
             prior to randomization

          6. Contra indications to treatment with hydroxychloroquine, known G6PD deficiency
             (anamnestic information, no test necessary) and psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Scheiner</last_name>
    <role>Study Director</role>
    <affiliation>Sotio a.s.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jindřichův Hradec</city>
        <zip>377 38</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nachod</city>
        <zip>547 69</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <zip>530 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pribram</city>
        <zip>261 95</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piest'any</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Metastatic</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Biological</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

